10Y annualized return is
positive but below market average
at 4.7% per year
AMGN has met or exceeded earnings expectations in
most
recent quarters (9/10)
Attractive Price-to-Earnings Ratio
Solid Price-to-Sales Ratio
High Price-to-Book Ratio
Elevated EV/EBITDA Ratio
Get access to all key takeaways, detailed financial metrics, and comprehensive stock analysis with our premium subscription.
Already have an account? Sign in
Overall, Amgen demonstrates strong business quality through robust revenue growth, a diverse product portfolio, and significant R&D investment. However, challenges with regulatory pressures and potential pricing declines may impact future performance. The company's future prospects appear positive, with promising growth drivers and a strong pipeline, though there are risks associated with competitive dynamics and market conditions.
Analysis Date: February 4, 2025
Last Updated: May 29, 2025
Past performance does not guarantee future results. The data presented is indicative and may not be updated in real-time.
Amgen Inc. is a company that makes medicines to help treat various health problems, such as cancer, bone diseases, and heart issues. They create products like Enbrel for arthritis and Neulasta to protect cancer patients from infections. Amgen works with doctors and hospitals to provide these treatments to patients all around the world. Founded in 1980 and based in California, Amgen is dedicated to improving people's health through their innovative therapies.
Streams of revenue
Geographic Distribution
Core Products
Business Type
Business to Business
Competitive Advantages
Discover all competitive advantages and strategic moats that protect AMGN's market position.
View Premium AnalysisKey Business Risks
Get comprehensive insight into all key business risks that could impact AMGN's performance.
Access Full Risk AnalysisLatest News
Trump's tariff policy is the latest uncertainty to plague the pharmaceutical sector.
When the stock market is highly volatile, many investors flock to assets that offer stability but dismal growth prospects. However, you don't necessar...
The Investment Committee give you their top stocks to watch for the second half.
Trailing Twelve Months (TTM) values provide a view of the company's performance over the last year.
Benjamin Graham's value investing approach focuses on finding stocks with a significant margin of safety between their intrinsic value and market price.
Access Benjamin Graham's value investing criteria, intrinsic value calculations, and margin of safety analysis
Trailing Twelve Months (TTM) values provide a view of the company's performance over the last year.
Profitability metrics measure a company's ability to generate earnings relative to its revenue, operating costs, and other relevant metrics. Higher values generally indicate better performance.
Access detailed profitability metrics with visual gauges and benchmarks
Access detailed analysis of profitability strengths and positive performance indicators
Upgrade to PremiumAccess detailed analysis of profitability weaknesses and areas of concern
Upgrade to PremiumFinancial health metrics assess a company's ability to meet its financial obligations and its overall financial stability.
Access detailed financial health metrics with visual gauges and risk assessments
Access detailed analysis of financial health strengths and stability indicators
Upgrade to PremiumAccess detailed analysis of financial health weaknesses and risk factors
Upgrade to PremiumMeeting Expectations
Higher values indicate better execution and credibility
Recent Results
View complete earnings history and detailed performance analysis
Upgrade to PremiumEPS
Revenue
Insider trading data shows purchase and sale activities by company executives and board members.
Insider trading patterns can provide insights into how company executives and board members view the stock's future prospects.
Get complete insider sentiment analysis with detailed trading patterns, sentiment indicators, and trend insights